| abstract |
FIELD: medicine. n SUBSTANCE: present disclosure relates to methods for treating ulcerative colitis in a patient in need of such treatment with a drug comprising a combination of the first and second compositions. First composition contains 5-aminosalicylic acid. Second composition is in the form of a separate tablet containing a tablet core containing 9 mg budesonide, a lipophilic excipient, an amphiphilic vehicle, a hydrophilic excipient, and a coating on the tablet core in the form of a gastric juice-resistant film. Prior to administration of the second composition, the patient was treated with the first composition, and said patient had a UCDAI index greater than or equal to 4. First and second compositions are administered simultaneously, separately or sequentially. Second composition is administered up to 8 weeks. n EFFECT: administration of the second composition with budesonide to patients who have previously taken or are now taking the first composition with 5-aminosalicylic acid, allows more effective treatment of ulcerative colitis and / or maintain a state of remission in the patient. n 14 cl, 8 tbl, 8 ex |